Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting Avirmax Biopharma is set to make a significant impact at the 2025 ARVO meeting with multiple presentations focused on ocular gene therapy advancements through its proprietary technologies.

Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting #Avirmax_Biopharma #AAV_Gene_Therapy #Dry_AMD

Avirmax Biopharma Launches Pioneering Gene Therapy Studies for Age-related Macular Degeneration Avirmax Biopharma begins pivotal studies for ABI-201, a groundbreaking gene therapy aimed at treating dry age-related macular degeneration and preserving vision.

Avirmax Biopharma Launches Pioneering Gene Therapy Studies for Age-related Macular Degeneration #United_States #Avirmax_Biopharma #gene_therapy #Hayward,_California #ABI-201

Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion Avirmax Biopharma has successfully completed the first cohort of patient enrollment for its ABI-110 clinical trial targeting Wet AMD and PCV, marking a significant milestone.

Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion #USA #Avirmax_Biopharma #Wet_AMD #ABI-110 #Hayward

Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD Avirmax Biopharma has commenced the Phase I/IIa trial of ABI-110, a pioneering gene therapy targeting Wet Age-related Macular Degeneration and PCV.

Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD #USA #Avirmax_Biopharma #Wet_AMD #ABI-110 #Hayward